What is your preferred choice of therapy for first-line treatment of a patient with good, intermediate, or poor risk stage III nonseminomatous germ cell tumor if the patient is truly cisplatin-ineligible?  

The first question is what makes the patient "cisplatin-ineligible". Cisplatin has been given in patients on hemodialysis, guided by cisplatin levels and timing of dialysis. In someone with first-line intermediate and poor-risk disease, cisplatin is indispensable in my view.